Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | NR2E3 | Q9Y5X4 | 3/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.38 |
| ▸ | STAT1 | P42224 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543657 | 1.00 | RAB9A (0.48) | RAB9ASMN1; SMN2NPC1HTTKDM4E | |
| SCHEMBL2779273 | 0.78 | SMN1; SMN2 (0.43) | RAB9ASMN1; SMN2NPC1HTTKDM4E | |
| SCHEMBL2779278 | 0.78 | SMN1; SMN2 (0.43) | RAB9ASMN1; SMN2NPC1HTTKDM4E | |
| SCHEMBL543428 | 0.77 | TBXAS1 (0.36) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL543427 | 0.77 | TBXAS1 (0.36) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL543656 | 0.75 | HSD17B1 (0.45) | RAB9ASMN1; SMN2NPC1HTTKDM4E | |
| SCHEMBL10258117 | 0.75 | HSD17B1 (0.45) | RAB9ASMN1; SMN2NPC1HTTKDM4E | |
| SCHEMBL24587500 | 0.74 | ALDH1A1 (0.44) | SMN1; SMN2HTTKDM4EALDH1A1MAPT | |
| SCHEMBL7947844 | 0.74 | ALDH1A1 (0.44) | SMN1; SMN2HTTKDM4EALDH1A1MAPT | |
| SCHEMBL543240 | 0.74 | CYP2A6 (0.44) | RAB9ASMN1; SMN2NPC1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110585-B2 | Bicyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, XDH | RAB9A 3544/4885SMN1; SMN2 1317/4885NPC1 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.